Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Sign up for alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Disease Models & Mechanisms
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Disease Models & Mechanisms

Advanced search

RSS   Twitter   Facebook   YouTube

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Sign up for alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
EDITORIAL
United states of amnesia: rescuing memory loss from diverse conditions
Clara Ortega-de San Luis, Tomás J. Ryan
Disease Models & Mechanisms 2018 11: dmm035055 doi: 10.1242/dmm.035055 Published 18 May 2018
Clara Ortega-de San Luis
1School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clara Ortega-de San Luis
Tomás J. Ryan
1School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland
2Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, VIC 3052, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomás J. Ryan
  • For correspondence: tomas.ryan@tcd.ie
  • Article
  • Figures & tables
  • Info & metrics
  • PDF
Loading

ABSTRACT

Amnesia – the loss of memory function – is often the earliest and most persistent symptom of dementia. It occurs as a consequence of a variety of diseases and injuries. These include neurodegenerative, neurological or immune disorders, drug abuse, stroke or head injuries. It has both troubled and fascinated humanity. Philosophers, scientists, physicians and anatomists have all pursued an understanding of how we learn and memorise, and why we forget. In the last few years, the development of memory engram labelling technology has greatly impacted how we can experimentally study memory and its disorders in animals. Here, we present a concise discussion of what we have learned about amnesia through the manipulation of engrams, and how we may use this knowledge to inform novel treatments of amnesia.

Introduction

Amnesia refers to a deficit of memory due to a specific cause. It is a disorder that arises as a consequence of more than 15 different types of diseases and injuries that affect the brain, such as neurodegenerative and neurological diseases, vascular disorders and traumatic lesions (Markowitsch and Staniloiu, 2012). It is often the earliest and most persistent symptom of dementia (Wells, 1979). Amnesia has a huge clinical significance – its effects on the daily life of patients who suffer from it can be enormous. As a result, there are many efforts towards developing successful treatments. Currently, therapeutic interventions are limited by the lack of understanding of how memory functions in both health and disease.

Memory is the ability to store information of past experiences in the brain. Knowledge learnt by animals alters their brain and modulates how the brain then regulates future behaviour. Understanding memory, and its mechanisms, is a central goal of modern neuroscience. In 1904, Richard Semon postulated that experiences provoke long-lasting changes in specific neurons that result in an enduring memory trace – an engram of the acquired information. Reactivation of these engram cells will result in the recall of that particular memory (Semon, 1904). To understand the mechanisms of engram formation, we have primarily relied on indirect methodological approaches, for example, by studying amnesia. The general approach is to interfere with a brain region, physiological process or gene that we hypothesize is important for memory, and then look for experimental amnesia in a given behavioural paradigm (McGaugh, 2000). Recently, we have begun to make progress in our understanding of both memory and amnesia through the development of memory engram technology.

Memory engram technology is based on the combination of transgenic, optogenetic, behavioural and electrophysiological approaches. Developed originally by Tonegawa and colleagues, the technology integrates optogenetics and immediate early gene (IEG) labelling to drive the expression of a transgene in cells that specifically respond to an experience (Boyden et al., 2005; Reijmers et al., 2007; Tonegawa et al., 2015a,b). In its first demonstration, a promoter of the IEG c-fos was used to drive the expression of channelrhodopsin (ChR2), a light-responsive ion channel, in hippocampal dentate gyrus neurons that were activated by a target contextual experience (Fig. 1). Temporal control is allowed by the tetracycline-controlled transactivator (tTA)-tetracycline response element (TRE) system, inducible by the removal of the antibiotic doxycycline so that it only labels the neurons that are responding to the controlled contextual experience. This approach demonstrated that direct activation of engram neurons for contextual memories associated with fear/threat is sufficient (Liu et al., 2012; Ramirez et al., 2013), as well as necessary (Denny et al., 2014; Tanaka et al., 2014; Trouche et al., 2016), to recall this specific episodic memory.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Engram labelling technology and memory retrieval in retrograde amnesia. (A) The promoter of the immediate early gene (IEG) drives expression of tTA in an activity-dependent manner. Doxycycline (DOX), which is delivered through the animal's diet, prevents tTA from binding to the TRE element of the channelrhodopsin (ChR2) transgene in hippocampal dentate gyrus (DG) neurons. (B) Shock delivery, which causes fear, in context A subsequently elicits a freezing response specifically to context A. In the absence of DOX, DG neurons that are active during the encoding of that fear memory express ChR2. Injection of the drug anisomycin after the encoding induces retrograde amnesia. (C) Amnesic animals are unable to elicit a behavioural (freezing) response using natural cues. (D) Optogenetic activation of engram neurons induces the recall of a distributed and context-specific fear response in amnesic animals.

Amnesia

From the clinical point of view, amnesia is described as a multifaceted disorder with a frequently poor prognosis (Markowitsch and Staniloiu, 2012). Anterograde amnesia refers to the inability to acquire and retain new information, whereas retrograde amnesia affects the recall of past or recently learned memories. Recent memories are more vulnerable to amnesia than older ones, and this is known as Ribot's law of regression (Ribot, 1881). Amnesia appears as a consequence of diverse clinical disorders, such as Alzheimer's and Parkinson's disease (AD and PD, respectively), depression, and head trauma, among many others. Therefore, animal models for those disorders frequently develop memory deficits (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Cause, effect and animal models of amnesia

Can the combination of memory engram labelling technology and disease models help us to understand the neuropathology of amnesia? In a model of drug-induced amnesia, mice administered with a protein synthesis inhibitor after a fear-inducing training session develop retrograde amnesia for that fear memory (McGaugh, 2000). Surprisingly, using the engram labelling technology, optogenetic activation of neurons in these mice elicited a context-specific fear response, indicating that the memory was still there (Fig. 1) (Ryan et al., 2015). This approach opens the possibility that the information is not completely lost in retrograde amnesia, but it is just inaccessible.

The same methodological approach was subsequently applied to models of early AD – the major neurodegenerative disease that affects memory storage (Roy et al., 2016; Perusini et al., 2017). AD is associated with the deposition of amyloid-β peptide in extracellular plaques and with the aggregation of the microtubule-associated protein tau in neurofibrillary tangles inside neurons (Braak and Braak, 1991). As a consequence of these aggregates, synapses are compromised, and there is selective neuronal death and a decrease in specific neurotransmitters (reviewed in Masters et al., 2015). The APP/PS1 mouse model recapitulates many of the hallmarks of human AD, including deficits in spatial, social and cognitive memory (Gong et al., 2004; Lalonde et al., 2005), but some strategies have successfully improved cognition in these models. Environmental enrichment was shown to be beneficial by stimulation of synaptic activity (Jankowsky et al., 2005; Lazarov et al., 2005; Fischer et al., 2007). Photonic stimulation of the visual cortex by chronic application of light in frequencies of 40 Hz improved contextual and fear memory, and significantly reduced amyloid-β plaque deposition (Iaccarino et al., 2016). Although these studies show that certain activities and interventions can ameliorate the deterioration of memory, they do not show whether the engram itself survives amnesia. In the APP/PS1 mouse model, short-term memories (minutes to hours) are intact, whereas long-term memories (a day or more) are compromised, indicating a consolidation deficit as a cause of the amnesia (Kilgore et al., 2010; Ryan et al., 2015). The fact that this kind of amnesia is retrograde (because the initial short-term memory is observed) indicates that the engram might still be present in the brain. Using the engram tagging approach in this model, animals with amnesia due to early-stage AD were able to remember a contextual memory through optogenetic stimulation of the labelled engram neurons. This proved that, firstly, the memory is maintained and, secondly, the cells responsible for encoding the original memory are not properly reactivated in early-stage AD models (Roy et al., 2016; Perusini et al., 2017). Furthermore, engram technology has provided insights into the role of memory loss in depression. Based on human studies, it has been hypothesized that depression may be due in part to a loss of access to positive memories (Dalgleish and Werner-Seidler, 2014). Engram technology has provided strong experimental evidence in favour of this idea. When positive or pleasurable memory engrams were labelled in the mouse hippocampus prior to the induction of depression, subsequent optogenetic stimulation of these engram cells ameliorated depressive behaviour, and chronic stimulation seemed to induce new plasticity in those cells that restored natural access to the engram and normal behaviour thereafter (Ramirez et al., 2015).

Treatment of amnesia

The idea that the information survives in the context of the pathology is changing the paradigm of amnesia and instigating the search for therapeutic strategies to make seemingly lost memories obtainable again, rather than simply preventing the memory loss in the first place. Such therapeutics would have wide-ranging utility, since amnesia is a common symptom of many different brain disorders (Table 1). The first objective will be to identify which kinds of retrograde (and perhaps in some cases, anterograde) amnesia are due to retrieval deficits. The subsequent step will be to find ways to restore access to those engrams in a sustainable manner. Animal studies are best placed to achieve both these initial aims before the strategies can be translated into human clinical cases. Importantly, any treatment or intervention designed to reverse amnesia, whether chronic or acute, needs to also be tested in control wild-type animals. This is crucial to account for general cognitive effects (e.g. arousal, attention, emotional response, etc.) that might affect behavioural performance independently of any improvement of memory engram function.

However, such approaches to ameliorate or reverse amnesia need to be complemented with continuing efforts to address the underlying cause of the disorder. This is especially the case for chronic forms of amnesia, as the memory will become inaccessible again if the problem is still present, such as in neurodegenerative disorders. Since amnesia is not the primary cause of these diseases, efforts put into finding therapies that palliate the memory deficits should be tied to therapies designed to stop the overall progress of the amnesia-causing disease in question.

What achievements in treating amnesia should be expected in the short and long term? Therapies based on optogenetic stimulation are very invasive, and this is a major obstacle to their translation to the clinic. The light required to optogenetically stimulate labelled neurons needs to be delivered through optic fibres, and gene therapy is required to make cells susceptible to light-mediated activation. This limitation might be overcome in the future by the development of the next-generation optogenetic implantable devices (Zhao and Hubin, 2017; Rudmann et al., 2018; Shoffstall et al., 2018) and by optimization of gene delivery (Dobson, 2006; Wang et al., 2017). Examples of non-invasive alternatives to target and activate engrams are transcranial direct-current stimulation (tDCS) and transcranial magnetic stimulation (TMS). tCDS applies weak electrical currents with electrodes that either hyperpolarize or depolarize the neurons to modify brain function. TMS achieves the same effect by generating a magnetic field inside a coiled wire that in turn generates an electrical field at the intracranial level. Although safer and much less invasive, the benefits of tDCS and TMS on cognitive function in AD are acute and not maintained in the long term (Freitas et al., 2011), probably because of their lack of specificity in targeting neurons. Most crucially, unlike researchers, physicians are not generally present at the time of memory engram formation in the patient's brain, and so are not in the privileged observational position to label human engrams in clinical cases, even if safe and appropriate technology was available. However, given the progress in the past 10 years, there is every reason to be optimistic about future possibilities of overcoming this caveat.

As memory engram technology has become available as a new tool, the memory research field has advanced in its understanding of memory storage, consolidation and retrieval processes. Combining these approaches with disease models associated with amnesia will help us better understand the pathology on a neurobiological level, and this would certainly be followed by better management and therapeutic treatment of patients affected by memory loss.

Acknowledgements

We thank Lydia Marks for proofreading.

Footnotes

  • Funding

    This work was supported by the European Research Council (C.O.S. and T.R.), Science Foundation Ireland and Jacobs Foundation (T.R.).

  • © 2018. Published by The Company of Biologists Ltd
http://creativecommons.org/licenses/by/3.0

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

    1. Ahmad, A.,
    2. Ramakrishna, S.,
    3. Meara, J. and
    4. Doran, M.
    (2010). Autoimmune limbic encephalitis: a reversible form of rapidly progressive amnesia and seizures. J. R. Coll. Physicians Edinb. 40, 123-125. doi:10.4997/JRCPE.2010.208
    OpenUrlCrossRefPubMed
    1. Albert, M. S.,
    2. Butters, N. and
    3. Levin, J.
    (1979). Temporal gradients in the retrograde amnesia of patients with alcoholic Korsakoff's Disease. Arch. Neurol. 36, 211-216. doi:10.1001/archneur.1979.00500400065010
    OpenUrlCrossRefPubMedWeb of Science
    1. Aleman, A.,
    2. Hijman R.,
    3. de Haan, E. H. and
    4. Kahn, R. S.
    (1999). Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 156, 1358-1366.
    OpenUrlPubMedWeb of Science
    1. Almeida-Suhett, C. P.,
    2. Prager, E. M.,
    3. Pidoplichko, V.,
    4. Figueiredo, T. H.,
    5. Marini, A. M.,
    6. Li, Z.,
    7. Eiden, L. E. and
    8. Braga, M. F. M.
    (2015). GABAergic interneuronal loss and reduced inhibitory synaptic transmission in the hippocampal CA1 region after mild traumatic brain injury. Exp. Neurol. 273, 11-23. doi:10.1016/j.expneurol.2015.07.028
    OpenUrlCrossRefPubMed
    1. Almli, C. R.,
    2. Levy, T. J.,
    3. Han, B. H.,
    4. Shah, A. R.,
    5. Gidday, J. M. and
    6. Holtzman, D. M.
    (2000).BDNF protects against spatial memory deficits following neonatal hypoxia-ischemia. Exp. Neurol. 166, 99-114. doi:10.1006/exnr.2000.7492
    OpenUrlCrossRefPubMedWeb of Science
    1. Arena, J. E. and
    2. Rabinstein, A. A.
    (2015). Transient global amnesia. Mayo Clin. Proc. 90, 264-272. doi:10.1016/j.mayocp.2014.12.001
    OpenUrlCrossRef
    1. Beatty, W. W.,
    2. Goodkin, D. E.,
    3. Monson, N.,
    4. Beatty, P. A. and
    5. Hertsgaard, D.
    (1988a). Anterograde and retrograde amnesia in patients with chronic progressive multiple sclerosis. Arch. Neurol. 45, 611-619. doi:10.1001/archneur.1988.00520300029013
    OpenUrlCrossRefPubMedWeb of Science
    1. Beatty, W. W.,
    2. Salmon, D. P.,
    3. Butters, N.,
    4. Heindel, W. C. and
    5. Granholm, E. L.
    (1988b). Retrograde amnesia in patients with Alzheimer's disease or Huntington's disease. Neurobiol. Aging 9, 181-186. doi:10.1016/S0197-4580(88)80048-4
    OpenUrlCrossRefPubMedWeb of Science
    1. Beers, D. R.,
    2. Henkel, J. S.,
    3. Kesner, R. P. and
    4. Stroop, W. G.
    (1995). Spatial recognition memory deficits without notable CNS pathology in rats following herpes simplex encephalitis. J. Neurol. Sci. 131, 119-127. doi:10.1016/0022-510X(95)00099-N
    OpenUrlCrossRefPubMed
  1. ↵
    1. Boyden, E. S.,
    2. Zhang, F.,
    3. Bamberg, E.,
    4. Nagel, G. and
    5. Deisseroth, K.
    (2005). Millisecond-timescale, genetically targeted optical control of neural activity. Nat. Neurosci. 8, 1263-1268. doi:10.1038/nn1525
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Braak, H. and
    2. Braak, E.
    (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica. 239-259. doi:10.1007/BF00308809
    OpenUrlCrossRefPubMedWeb of Science
    1. Burt, D. B.,
    2. Zembar, M. J. and
    3. Niederehe, G.
    (1995). Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol. Bull. 117, 285-305. doi:10.1037/0033-2909.117.2.285
    OpenUrlCrossRefPubMedWeb of Science
    1. Butters, N. and
    2. Cermak, L. S.
    (1974). Some comments on Warrington and Baddeley's report of normal short-term memory in amnesic patients. Neuropsychologia 12, 283-285. doi:10.1016/0028-3932(74)90014-1
    OpenUrlCrossRefPubMed
    1. Cermak, L. S. and
    2. O'connor, M.
    (1983). The anterograde and retrograde retrieval ability of a patient with amnesia due to encephalitis. Neuropsychologia 21, 213-234. doi:10.1016/0028-3932(83)90039-8
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Dalgleish, T. and
    2. Werner-Seidler, A.
    (2014). Disruptions in autobiographical memory processing in depression and the emergence of memory therapeutics. Trends Cogn. Sci. 18, 596-604. doi:10.1016/j.tics.2014.06.010
    OpenUrlCrossRefPubMed
    1. Davis, H. P. and
    2. Squire, L. R.
    (1984). Protein synthesis and memory: a review. Psychol. Bull. 96, 518-559. doi:10.1037/0033-2909.96.3.518
    OpenUrlCrossRefPubMedWeb of Science
    1. De Renzi, E. and
    2. Lucchelli, F.
    (1993). Dense retrograde amnesia, intact learning capability and abnormal forgetting rate: a consolidation deficit? Cortex. Masson Italia Periodici S.r.l., 29, 449-466. doi:10.1016/S0010-9452(13)80253-5
    OpenUrlCrossRef
  4. ↵
    1. Denny, C. A.,
    2. Kheirbek, M. A.,
    3. Alba, E. L.,
    4. Tanaka, K. F.,
    5. Brachman, R. A.,
    6. Laughman, K. B.,
    7. Tomm, N. K.,
    8. Turi, G. F.,
    9. Losonczy, A. and
    10. Hen, R.
    (2014). Hippocampal memory traces are differentially modulated by experience, time, and adult neurogenesis. Neuron 83, 189-201. doi:10.1016/j.neuron.2014.05.018
    OpenUrlCrossRefPubMed
  5. ↵
    1. Dobson, J.
    (2006). Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 13, 283-287. doi:10.1038/sj.gt.3302720
    OpenUrlCrossRefPubMedWeb of Science
    1. Engmann, O.,
    2. Hortobágyi, T.,
    3. Pidsley, R.,
    4. Troakes, C.,
    5. Bernstein, H. G.,
    6. Kreutz, M. R.,
    7. Mill, J.,
    8. Nikolic, M. and
    9. Giese, K. P.
    (2011). Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. Brain 134, 2408-2421. doi:10.1093/brain/awr155
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Fischer, A.,
    2. Sananbenesi, F.,
    3. Wang, X.,
    4. Dobbin, M. and
    5. Tsai, L.-H.
    (2007). Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178-182. doi:10.1038/nature05772
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Freitas, C.,
    2. Mondragón-Llorca, H. and
    3. Pascual-Leone, A.
    (2011). Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future. Exp. Gerontol. 46, 611-627. doi:10.1016/j.exger.2011.04.001
    OpenUrlCrossRefPubMed
    1. Goldberg, E.,
    2. Antin, S.,
    3. Bilder, R.,
    4. Gerstman, L.,
    5. Hughes, J. and
    6. Mattis, S.
    (1981). Retrograde amnesia: possible role of mesencephalic reticular activation in long-term memory. Science 213, 1392-1394. doi:10.1126/science.7268442
    OpenUrlFREE Full Text
  8. ↵
    1. Gong, B.,
    2. Vitolo, O. V.,
    3. Trinchese, F.,
    4. Liu, S.,
    5. Shelanski, M. and
    6. Arancio, O.
    (2004). Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Investig. 114, 1624-1634. doi:10.1172/JCI22831
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Iaccarino, H. F.,
    2. Singer, A. C.,
    3. Martorell, A. J.,
    4. Rudenko, A.,
    5. Gao, F.,
    6. Gillingham, T. Z.,
    7. Mathys, H.,
    8. Seo, J.,
    9. Kritskiy, O.,
    10. Abdurrob, F. et al.
    (2016). Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540, 230-235. doi:10.1038/nature20587
    OpenUrlCrossRefPubMed
  10. ↵
    1. Jankowsky, J. L.,
    2. Melnikova, T.,
    3. Fadale, D.J.,
    4. Xu, G.M.,
    5. Slunt, H.H.,
    6. Gonzales, V.,
    7. Younkin, L.H.,
    8. Younkin, S.G.,
    9. Borchelt, D.R. and
    10. Savonenko, A.V.
    (2005). Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 25, 5217-5224. doi:10.1523/JNEUROSCI.5080-04.2005
    OpenUrlAbstract/FREE Full Text
    1. Kapur, N.
    (1993). Transient epileptic amnesia--a clinical update and a reformulation. J. Neurol. Neurosurg. Psychiatry 56, 1184-1190. doi:10.1136/jnnp.56.11.1184
    OpenUrlAbstract/FREE Full Text
    1. Kapur, N.
    (1999). Syndromes of retrograde amnesia: a conceptual and empirical synthesis. Psychol. Bull. 125, 800-825. doi:10.1037/0033-2909.125.6.800
    OpenUrlCrossRefPubMedWeb of Science
    1. Kapur, N.,
    2. Mclellan, D. L. and
    3. Burrows, E. H.
    (1992). Focal retrograde amnesia following bilateral temporal lobe pathology. A neuropsychological and magnetic resonance study. Brain: J.l Neurol. 115, 73-85. doi:10.1093/brain/115.1.73
    OpenUrlCrossRefPubMedWeb of Science
    1. Kesner, R. P.,
    2. Dixon, D. A.,
    3. Pickett, D. and
    4. Berman, R. F.
    (1975). Experimental animal model of transient global amnesia: role of the hippocampus. Neuropsychologia 13, 465-480. doi:10.1016/0028-3932(75)90070-6
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Kilgore, M.,
    2. Miller, C. A.,
    3. Fass, D. M.,
    4. Hennig, K. M.,
    5. Haggarty, S. J.,
    6. Sweatt, J. D. and
    7. Rumbaugh, G.
    (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870-880. doi:10.1038/npp.2009.197
    OpenUrlCrossRefPubMedWeb of Science
    1. Kim, D. Y.,
    2. Hao, J.,
    3. Liu, R.,
    4. Turner, G.,
    5. Shi, F.-D. and
    6. Rho, J. M.
    (2012). Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS ONE 7, e35476. doi:10.1371/journal.pone.0035476
    OpenUrlCrossRefPubMed
    1. Kinoshita, K.,
    2. Muroi, Y.,
    3. Unno, T. and
    4. Ishii, T.
    (2017). Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. J. Pharmacol. Sci., 134, 55-58. doi:10.1016/j.jphs.2017.04.002
    OpenUrlCrossRef
    1. Kopelman, M. D.
    (1992). Storage, forgetting, and retrieval in the anterograde and retrograde amnesia of the Alzheimer's type. Memory functioning in dementia, pp. 45-71.
    1. Kuroda, T.,
    2. Futamura, A.,
    3. Sugimoto, A.,
    4. Midorikawa, A.,
    5. Honma, M. and
    6. Kawamura, M.
    (2015). Autobiographical age awareness disturbance syndrome in autoimmune limbic encephalitis: two case reports. BMC Neurol. 15, 238. doi:10.1186/s12883-015-0498-7
    OpenUrlCrossRef
  12. ↵
    1. Lalonde, R.,
    2. Kim, H. D.,
    3. Maxwell, J. A. and
    4. Fukuchi, K.
    (2005). Exploratory activity and spatial learning in 12-month-old APP695SWE/co+PS1/ΔE9 mice with amyloid plaques. Neurosci. Lett. 390, 87-92. doi:10.1016/j.neulet.2005.08.028
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Lazarov, O.,
    2. Robinson, J.,
    3. Tang, Y.-P.,
    4. Hairston, I. S.,
    5. Korade-Mirnics, Z.,
    6. Lee, V. M.-Y.,
    7. Hersh, L. B.,
    8. Sapolsky, R. M.,
    9. Mirnics, K. and
    10. Sisodia, S. S.
    (2005). Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell, 120, 701-713. doi:10.1016/j.cell.2005.01.015
    OpenUrlCrossRefPubMedWeb of Science
    1. Lister, R. G.
    (1985). The amnesic action of benzodiazepines in man. Neurosci. Biobehav. Rev. 9, 87-94. doi:10.1016/0149-7634(85)90034-X
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Liu, X.,
    2. Ramirez, S.,
    3. Pang, P. T.,
    4. Puryear, C. B.,
    5. Govindarajan, A.,
    6. Deisseroth, K. and
    7. Tonegawa, S.
    (2012). Optogenetic stimulation of a hippocampal engram activates fear memory recall. Nature 484, 381-385. doi:10.1038/nature11028.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Markowitsch, H. J. and
    2. Staniloiu, A.
    (2012). Amnesic disorders. Lancet 380, 1429-1440. doi:10.1016/S0140-6736(11)61304-4
    OpenUrlCrossRefPubMed
  16. ↵
    1. Masters, C. L.,
    2. Bateman, R.,
    3. Blennow, K.,
    4. Rowe, C. C.,
    5. Sperling, R. A. and
    6. Cummings, J. L.
    (2015). Alzheimer's disease. Nat. Rev. Dis. Primers. 1, 1-18. doi:10.1038/nrdp.2015.56
    OpenUrlCrossRef
  17. ↵
    1. Mcgaugh, J. L.
    (2000). Memory--a century of consolidation. Science (New York, N.Y.) 287, 248-251. doi:10.1126/science.287.5451.248
    OpenUrlAbstract/FREE Full Text
    1. Michel, P.,
    2. Beaud, V.,
    3. Eskandari, A.,
    4. Maeder, P.,
    5. Demonet, J. F. and
    6. Eskioglou, E.
    (2017). Ischemic amnesia. Stroke 48, 2270-2273. doi:10.1161/STROKEAHA.117.017420
    OpenUrlAbstract/FREE Full Text
    1. Misanin, J. R.,
    2. Miller, R. R. and
    3. Lewis, D. J.
    (1968). Retrograde amnesia produced by electroconvulsive shock after reactivation of a consolidated memory trace. Science 160, 554-555. doi:10.1126/science.160.3827.554
    OpenUrlAbstract/FREE Full Text
    1. Pang, T. Y. C.,
    2. Stam, N. C.,
    3. Nithianantharajah, J.,
    4. Howard, M. L. and
    5. Hannan, A. J.
    (2006). Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in huntington's disease transgenic mice. Neuroscience 141, 569-584. doi:10.1016/j.neuroscience.2006.04.013
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Perusini, J. N.,
    2. Cajigas, S. A.,
    3. Cohensedgh, O.,
    4. Lim, S. C.,
    5. Pavlova, I. P.,
    6. Donaldson, Z. R. and
    7. Denny, C. A.
    (2017). Optogenetic stimulation of dentate gyrus engrams restores memory in Alzheimer's disease mice. Hippocampus 27, 1110-1122. doi:10.1002/hipo.22756
    OpenUrlCrossRef
  19. ↵
    1. Ramirez, S.,
    2. Liu, X.,
    3. Lin, P.-A.,
    4. Suh, J.,
    5. Pignatelli, M.,
    6. Redondo, R. L.,
    7. Ryan, T. J. and
    8. Tonegawa, S.
    (2013). Creating a false memory in the hippocampus. Science 341, 387-391. doi:10.1126/science.1239073
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Ramirez, S.,
    2. Liu, X.,
    3. Macdonald, C. J.,
    4. Moffa, A.,
    5. Zhou, J.,
    6. Redondo, R. L. and
    7. Tonegawa, S.
    (2015). Activating positive memory engrams suppresses depression-like behaviour. Nature 522, 335-339. doi:10.1038/nature14514
    OpenUrlCrossRefPubMed
    1. Rau, V.,
    2. Decola, J. P. and
    3. Fanselow, M. S.
    (2005). Stress-induced enhancement of fear learning: An animal model of posttraumatic stress disorder. Neurosci. Biobehav. Rev. 1207-1223. doi:10.1016/j.neubiorev.2005.04.010
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Reijmers, L. G.,
    2. Perkins, B. L.,
    3. Matsuo, N. and
    4. Mayford, M.
    (2007). Localization of a stable neural correlate of associative memory. Science 317, 1230-1233. doi:10.1126/science.1143839
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Ribot, T. A.
    (1881). Diseases of memory-an essay in the positive psychology, the international scientific series, Vol. XLI. Diseases of memory: An Essay in the Positive Psychology, The International Scientific Series, Volume XLI, p. 236.
  23. ↵
    1. Roy, D. S.,
    2. Arons, A.,
    3. Mitchell, T. I.,
    4. Pignatelli, M.,
    5. Ryan, T. Ã. ¡ J. and
    6. Tonegawa, S.
    (2016). Memory retrieval by activating engram cells in mouse models of early Alzheimer's disease. Nature 531, 508-512. doi:10.1038/nature17172
    OpenUrlCrossRefPubMed
  24. ↵
    1. Rudmann, L.,
    2. Alt, M. T.,
    3. Ashouri Vajari, D. and
    4. Stieglitz, T.
    (2018). Integrated optoelectronic microprobes. Curr. Opin. Neurobiol. 50, 72-82. doi:10.1016/j.conb.2018.01.010
    OpenUrlCrossRef
  25. ↵
    1. Ryan, T. J.,
    2. Roy, D. S.,
    3. Pignatelli, M.,
    4. Arons, A. and
    5. Tonegawa, S.
    (2015). Engram cells retain memory under retrograde amnesia. Science 348, 1007-1013. doi:10.1126/science.aaa5542
    OpenUrlAbstract/FREE Full Text
    1. Sackeim, H. A.,
    2. Prudic, J.,
    3. Devanand, D. P.,
    4. Nobler, M. S.,
    5. Lisanby, S. H.,
    6. Peyser, S.,
    7. Fitzsimons, L.,
    8. Moody, B. J. and
    9. Clark, J.
    (2000). A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch. Gen. Psychiatry 57, 425. doi:10.1001/archpsyc.57.5.425
    OpenUrlCrossRefPubMedWeb of Science
    1. Savage, L. M.,
    2. Hall, J. M. and
    3. Resende, L. S.
    (2012). Translational rodent models of korsakoff syndrome reveal the critical neuroanatomical substrates of memory dysfunction and recovery. Neuropsychol. Rev. 22, 195-209. doi:10.1007/s11065-012-9194-1
    OpenUrlCrossRefPubMed
    1. Schuckit, M. A.
    (2009). Alcohol-use disorders. Lancet 373, 492-501. doi:10.1016/S0140-6736(09)60009-X
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Semon, R.
    (1904). Die mneme [The mneme]. Edited by W. Engelmann. Leipzig.
  27. ↵
    1. Shoffstall, A. J.,
    2. Srinivasan, S.,
    3. Willis, M.,
    4. Stiller, A. M.,
    5. Ecker, M.,
    6. Voit, W. E.,
    7. Pancrazio, J. J. and
    8. Capadona, J. R.
    (2018). A mosquito inspired strategy to implant microprobes into the brain. Sci. Rep. 8, 122. doi:10.1038/s41598-017-18522-4
    OpenUrlCrossRef
    1. Staniloiu, A.,
    2. Markowitsch, H. J. and
    3. Kordon, A.
    (2018). Psychological causes of autobiographical amnesia: a study of 28 cases. Neuropsychologia 110, 134-147. doi:10.1016/j.neuropsychologia.2017.10.017
    OpenUrlCrossRef
    1. Sullivan, E. V. and
    2. Fama, R.
    (2012). Wernicke's encephalopathy and Korsakoff's syndrome revisited. Neuropsychol. Rev. 22, 69-71. doi:10.1007/s11065-012-9205-2
    OpenUrlCrossRefPubMed
  28. ↵
    1. Tanaka, K. Z.,
    2. Pevzner, A.,
    3. Hamidi, A. B.,
    4. Nakazawa, Y.,
    5. Graham, J.,
    6. Wiltgen, B. J.
    (2014). Cortical representations are reinstated by the hippocampus during memory retrieval. Neuron 84, 347-354. doi:10.1016/j.neuron.2014.09.037
    OpenUrlCrossRefPubMed
  29. ↵
    1. Tonegawa, S.,
    2. Liu, X.,
    3. Ramirez, S. and
    4. Redondo, R.
    (2015a). Memory engram cells have come of age. Neuron 87, 918-931. doi:10.1016/j.neuron.2015.08.002
    OpenUrlCrossRefPubMed
  30. ↵
    1. Tonegawa, S.,
    2. Pignatelli, M.,
    3. Roy, D. S. and
    4. Ryan, T. J.
    (2015b). Memory engram storage and retrieval. Curr. Opin. Neurobiol. 35, 101-109. doi:10.1016/j.conb.2015.07.009
    OpenUrlCrossRefPubMed
  31. ↵
    1. Trouche, S.,
    2. Perestenko, P. V.,
    3. Van De Ven, G. M.,
    4. Bratley, C. T.,
    5. Mcnamara, C. G.,
    6. Campo-Urriza, N.,
    7. Black, S. L.,
    8. Reijmers, L. G. and
    9. Dupret, D.
    (2016). Recoding a cocaine-place memory engram to a neutral engram in the hippocampus. Nat. Neurosci. 19, 564-567. doi:10.1038/nn.4250
    OpenUrlCrossRefPubMed
    1. Van Der Kolk, B. A.
    (1994). The body keeps the score: memory and the evolving psychobiology of posttraumatic stress. Harv. Rev. Psychiatry. 1, 253-265. doi:10.3109/10673229409017088
    OpenUrlCrossRefPubMedWeb of Science
    1. Viana, M. B.,
    2. Tomaz, C. and
    3. Graeff, F. G.
    (1994). The elevated T-maze: A new animal model of anxiety and memory. Pharmacology 49, 549-554. doi:10.1016/0091-3057(94)90067-1
    OpenUrlCrossRefPubMed
  32. ↵
    1. Wang, S.,
    2. Kugelman, T.,
    3. Buch, A.,
    4. Herman, M.,
    5. Han, Y.,
    6. Karakatsani, M.E.,
    7. Hussaini, S.A.,
    8. Duff, K. and
    9. Konofagou, E.E.
    (2017). Non-invasive, focused ultrasound-facilitated gene delivery for optogenetics. Sci. Rep. 7, 39955. doi:10.1038/srep39955
    OpenUrlCrossRef
    1. Warrington, E. K. and
    2. Mccarthy, R. A.
    (1988). The fractionation of retrograde amnesia. Brain Cogn. 7, 184-200. doi:10.1016/0278-2626(88)90029-2
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Wells, C. E.
    (1979). Diagnosis of dementia. Psychosomatics 20, 517-522. doi:10.1016/S0033-3182(79)70774-2
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Zhao, H. and
    2. Hubin
    , (2017). Recent progress of development of optogenetic implantable neural probes. Int. J. Mol. Sci. 18, 1751. doi:10.3390/ijms18081751
    OpenUrlCrossRef
    1. Zola-Morgan, S.
    (1996). Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. Neurocase 2, 259aw-25298. doi:10.1093/neucas/2.4.259-aw
    OpenUrlCrossRef
View Abstract
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

RSSRSS

 Download PDF

Email

Thank you for your interest in spreading the word on Disease Models & Mechanisms.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
United states of amnesia: rescuing memory loss from diverse conditions
(Your Name) has sent you a message from Disease Models & Mechanisms
(Your Name) thought you would like to see the Disease Models & Mechanisms web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
EDITORIAL
United states of amnesia: rescuing memory loss from diverse conditions
Clara Ortega-de San Luis, Tomás J. Ryan
Disease Models & Mechanisms 2018 11: dmm035055 doi: 10.1242/dmm.035055 Published 18 May 2018
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
EDITORIAL
United states of amnesia: rescuing memory loss from diverse conditions
Clara Ortega-de San Luis, Tomás J. Ryan
Disease Models & Mechanisms 2018 11: dmm035055 doi: 10.1242/dmm.035055 Published 18 May 2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • ABSTRACT
    • Introduction
    • Amnesia
    • Treatment of amnesia
    • Acknowledgements
    • Footnotes
    • References
  • Figures & tables
  • Info & metrics
  • PDF

Related articles

Cited by...

More in this TOC section

  • Disease Models & Mechanisms announces a new Editor-in-Chief
  • Travel grants and how to use them (when there's no travel)
  • DMM Outstanding Paper Prize 2019 winner: Alessandro Bailetti
Show more EDITORIAL

Similar articles

Subject collections

  • Neurodegenerative Disorders
  • Editorials

Other journals from The Company of Biologists

Development

Journal of Cell Science

Journal of Experimental Biology

Biology Open

Advertisement

DMM and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.


Professor Elizabeth Patton appointed as DMM’s next Editor-in-Chief

We are pleased to announce that The Company of Biologists directors have appointed Professor Elizabeth Patton as DMM's new Editor-in-Chief. As Paresh Vyas writes in his Editorial, Liz ‘brings vitality and a passion for the remit of DMM, and is deeply embedded in the community.’


Did you know DMM Conference Travel Grants can be used for online meetings?

With travel restrictions still in place, we want to continue supporting early-career researchers in their careers. DMM’s Conference Travel Grants can now be used to attend virtual and online scientific meetings, workshops, conferences and training courses.

The current application round closes on 8 February 2021 – find out more.


Identification of MYOM2 as a candidate gene in hypertrophic cardiomyopathy and Tetralogy of Fallot, and its functional evaluation in the Drosophila heart

Research from Silke Sperling and colleagues uses Drosophila to identify MYOM2 as a candidate gene in congenital heart malformations in this issue’s Editor’s choice.


C. elegans as a disease model

A new Research article from Doyle et al., models spinal muscular atrophy in C. elegans to show that that targeting therapies to muscle cells is more effective than neuronal delivery. Find more research using C. elegans as a disease model in our latest subject collection.


Call for papers – The RAS Pathway: Diseases, Therapeutics and Beyond

Our upcoming special issue is now welcoming submissions until 1 April 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway. Find out more about the issue and how to submit your manuscript.


Interview – Kim Landry-Truchon and Nicolas Houde

In an interview, first authors Kim Landry-Truchon and Nicolas Houde discuss their mouse model of the early stages of pleuropulmonary blastoma, reflecting on the implications of their work and the future of their field.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Subject collections
  • Interviews
  • Sign up for alerts

About us

  • About DMM
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Journal Meetings
  • Workshops
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Sign up for alerts

Contact

  • Contact DMM
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2021   The Company of Biologists Ltd   Registered Charity 277992